Catalog12 refs
Ipamorelin
Growth Hormone SecretagogueGrowth Hormone / IGF-1 AxistherapeuticGrowth Hormone Secretagogue | Selective GHRPEndocrine & MetabolicGrowth HormoneResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Muscles
Overview
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by Novo Nordisk and derived from GHRP-1. It is an agonist of the ghrelin / growth hormone secretagogue receptor (GHS-R1a) on the somatotroph cells of the anterior pituitary, triggering intracellular signaling that makes the pituitary release stored GH in pulses, mimicking natural ghrelin. Its defining feature is selectivity: at GH-releasing doses it does not meaningfully raise ACTH, cortisol, prolactin, FSH, LH or TSH, making it cleaner than older peptides like GHRP-2 and GHRP-6. It was advanced into Phase II trials for postoperative ileus but was discontinued for insufficient efficacy.
Primary Uses
Growth hormone release stimulation
Postoperative recovery
Muscle growth
Anti-aging
Fat loss
Better sleep
Post-operative ileus (gut motility after surgery)
Age-related GH decline recovery
Selective GH release research
Sleep/recovery studies
IGF-1 modulation
Combination peptide protocols
Body weight gain in lean and obese models
Longitudinal bone growth
Postoperative ileus management
Gastrointestinal dysmotility
Cisplatin-induced weight loss and anorexia
Musculoskeletal injury and athletic performance research
Natural GH Stimulation
IGF-1 Enhancement
Anti-Aging Benefits
Lean Mass Development
Fat Loss Support
Sleep Quality
Exercise Recovery
Growth Hormone Release
IGF-1 Production
Muscle Growth Promotion
Bone Density Improvement
Cognitive Enhancement
Postoperative ileus (studied, discontinued)
Gut motility (research)
Anti-aging (extrapolated, unproven)
Fat loss (extrapolated, unproven)
Muscle gain (extrapolated, unproven)
Recovery (extrapolated, unproven)
Protocol Reference
Dose
200–300 mcg
Frequency
1-3x daily, fasted (before bed preferred)
Half-life
~2 Hours
Route
Subcutaneous
Evidence
Mixed Evidence / Phase 2 / Phase 2 clinical trials (discontinued for business reasons) / Well Studied / B / Phase II (discontinued for insufficient efficacy); mostly preclinical data (disputed)
Research References· 22
https://pubmed.ncbi.nlm.nih.gov/11735244/
PubMedPMID 11735244- [https://pubmed.ncbi.nlm.nih.gov/10828840/](https://pubmed.ncbi.nlm.nih.gov/10828840/)
Research Models
HumanPigRat
Also in Growth Hormone Secretagogue